Aflac Surges 3.43% on Strong Japan Sales Hits 319th in 360M Trading Volume

On August 6, 2025, Aflac (AFL) traded with a 3.43% gain, its volume reaching $360 million, ranking 319th in daily trading activity. The insurer’s Q2 2025 adjusted earnings of $1.78 per share exceeded estimates by 4.1%, driven by strong sales of its new Miraito cancer insurance product in Japan. However, revenue fell 11.7% to $4.5 billion, pressured by elevated expenses and reduced investment income in the U.S. segment.

Aflac’s Japan business saw 23.2% growth in new annualized premium sales, bolstered by Miraito’s launch, while U.S. operations reported 2.7% growth in new sales. Despite these gains, adjusted net investment income declined 5% in the U.S. due to lower floating-rate returns. Total acquisition and operating expenses rose 10.9% year-over-year, squeezing margins. The company’s Japan segment posted a 1.0% revenue increase, though pre-tax earnings fell 8.6% to $790 million.

Shareholder returns remained a focus, with $829 million in share buybacks and a 16% dividend increase to $0.58 per share. Aflac’s balance sheet showed $7 billion in cash and $27.2 billion in shareholder equity as of June 30, 2025. Management reiterated 2025 guidance for Japan’s benefit ratio of 64-66% and the U.S. at 48-52%, while expenses are expected to remain elevated due to product expansion and technology investments.

The strategy of purchasing the top 500 stocks by daily trading volume and holding for one day generated a 166.71% return from 2022 to the present, outperforming the benchmark by 137.53%. This highlights liquidity-driven momentum in volatile markets, though high-volume stocks may face risks from rapid trend shifts.